VX-661: Phase II started

Vertex disclosed in its 4Q11 earnings that it began a Phase II trial to evaluate VX-661 as monotherapy followed by VX-661 plus Kalydeco ivacaftor in CF patients with 2 copies of the F508del mutation,...